Capsugel, the world's leading hard capsule manufacturer and an innovator in drug delivery systems, today announced its acquisition of the FlexTab™ technology, a novel dosage form developed over the past 8 years within GlaxoSmithKline (GSK). The technology uses injection molding processes to produce unique capsule-shaped dosage forms that offer a new platform for formulating a wide range of new pharmaceutical and consumer health products. The deal between Capsugel and GSK was brokered by SR One, GSK's corporate venture fund.
"Capsugel is very excited to have this innovative technology as part of our suite of offerings," said Keith Hutchison, Vice President of Research and Development at Capsugel. "We believe that the FlexTab technology's unique performance characteristics and novel presentation will enable us to formulate the next generation of pharmaceutical and biotech products for our customers. With fewer new drug entities coming to market, our customers are looking for other ways to improve the therapeutic effectiveness of existing API's for patients and consumers, for example through better patient compliance and convenience."
The FlexTab technology allows for a variety of fill materials, including powders, pellets, liquids, micro-tablets and tablets, and can even deliver separate liquid and powder API's in one dose. This innovation opens the door to novel product designs and customization options. It extends Capsugel's capsule technology beyond the well-established dip-molding process used today, expanding into higher value segments and offering enhanced value for customers.
Capsugel is moving forward immediately to bring the technology and assets in-house with plans of making the new dosage form available to customers as soon as possible.
To learn more about Capsugel's unique drug delivery systems, visit our website at www.capsugel.com